Search Results - "Kell, W. Jonathan"

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells by Goodwin, Richard G., Kell, W. Jonathan, Laidler, Peter, Long, C. Colin, Whatley, Sharon D., McKinley, Mark, Badminton, Michael N., Burnett, Alan K., Williams, Geraint T., Elder, George H.

“…Late-onset erythropoietic protoporphyria (EPP) is a rare complication of myelodysplastic syndrome (MDS) but has not been described in association with a…”
Get full text

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy by Knapper, Steven, Burnett, Alan K., Littlewood, Tim, Kell, W. Jonathan, Agrawal, Sam, Chopra, Raj, Clark, Richard, Levis, Mark J., Small, Donald

“…Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are…”
Get full text

Aggressive treatment of HIV-associated microangiopathic haemolytic anaemia is associated with good outcome by Kell, W J, Dasani, H, Collins, P W

Get more information

A Phase 2 Evaluation of Single Agent Clofarabine as First Line Treatment for Older Patients with AML Who Are Not Considered Fit for Intensive Chemotherapy by Burnett, Alan K., Russell, Nigel, Kell, Jonathan W., Milligan, Donald, Culligan, Dominic

“…Patients over 70 years represent a significant proportion of patients with AML. They respond poorly to intensive chemotherapy. Although 50% of patients can…”
Get full text

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Commentary by STONE, Richard M, KNAPPER, Steven, BURNETT, Alan K, LITTLEWOOD, Tim, KELL, W. Jonathan, AGRAWAL, Sam, CHOPRA, Raj, CLARK, Richard, LEVIS, Mark J, SMALL, Donald

Get full text